Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune LlcfiledCriticalMedimmune Llc
Publication of TR201905227T4publicationCriticalpatent/TR201905227T4/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Burada, bir insan ICOS polipeptidine özgül olarak bağlanan, artan in vivo ADCC aktivitesi sergileyen ve solüsyonda tersinebilir kendiliğinden-birleşmeye maruz kalan antikorların ve bunların biyolojik olarak aktif fragmanlarının sıvı formülasyonları tarif edilmektedir.Liquid formulations of antibodies and biologically active fragments thereof are described herein that bind specifically to a human ICOS polypeptide, exhibit increased in vivo ADCC activity, and undergo reversible self-assembly in solution.
HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMABLE DEATH 1 PROTECTION (PD-1) AND METHODS OF CANCER TREATMENT USING ANTI-PD-1-ANTI-BODY, INDEPENDENTLY OR IN COMBINATION WITH OTHER IMMUNETURAH AND I And I And I And I, In The Combine, I And I Do Not Allocate To Them, Combined With Other Overarching
Binding protein capable of binding to dll4; antibody construct comprising said protein; antibody conjugate; nucleic acid, vector and host cell comprising the antibody; composition for the release of a binding protein; method to reduce the activity of human dll4.
Antibody or antigen-binding fragment thereof capable of binding human dll4; conjugate comprising said antibody; isolated vector and host cell; method of producing said antibody; pharmaceutical composition comprising it; and medical use of said antibody.
PREPARATION OF HETEROLOGICAL POLYPEPTIDES IN MICROWATEREDES, EXTRA-CELLED MICROWAVE-ALONG CALVES, COMPOSITIONS AND METHODS OF THEIR RECEIVING AND APPLICATION